These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 33633909)
1. Delusional Infestation Secondary to the Dopamine Agonist Ropirinole in a Patient With Parkinson's Disease: A Case Report With an Outline of the Biology of Psychosis. Kesserwani H Cureus; 2021 Jan; 13(1):e12880. PubMed ID: 33633909 [TBL] [Abstract][Full Text] [Related]
2. Delusional Infestation in Parkinson's Disease. Davis JL; Kurek JA; Sethi KD; Morgan JC Mov Disord Clin Pract; 2017; 4(1):111-115. PubMed ID: 30713955 [TBL] [Abstract][Full Text] [Related]
3. "Doctor, You Must Examine My Creature Collection!": A Case Report of Delusional Infestation. Cohen PR Cureus; 2022 Jun; 14(6):e25758. PubMed ID: 35812529 [TBL] [Abstract][Full Text] [Related]
4. Delusional Infestation in Parkinson's Disease Secondary to Piribedil Escalation: An Uncommon Case Report. Ahizoune A; Ait Berri M Cureus; 2024 Feb; 16(2):e53631. PubMed ID: 38449964 [TBL] [Abstract][Full Text] [Related]
6. qEEG in the Diagnosis and Prognosis of a Case with Delusional Infestation. Arıkan MK; İlhan R; Ozulucan MT; Aşık M Clin EEG Neurosci; 2024 Mar; 55(2):214-218. PubMed ID: 36945781 [TBL] [Abstract][Full Text] [Related]
7. Delusional parasitosis as premotor symptom of parkinson's disease: A case report. Oh M; Kim JW; Lee SM World J Clin Cases; 2022 Mar; 10(9):2858-2863. PubMed ID: 35434114 [TBL] [Abstract][Full Text] [Related]
8. Successful Treatment of Delusional Infestation with Olanzapine Depot. Vouk-Kamenski J; Vukojevic J; Celic I Alpha Psychiatry; 2021 Nov; 22(6):324-327. PubMed ID: 36448008 [TBL] [Abstract][Full Text] [Related]
9. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417 [TBL] [Abstract][Full Text] [Related]
10. Delusional parasitosis with folie à deux: A case series. Sawant NS; Vispute CD Ind Psychiatry J; 2015; 24(1):97-8. PubMed ID: 26257494 [TBL] [Abstract][Full Text] [Related]
11. Multiple D2 heteroreceptor complexes: new targets for treatment of schizophrenia. Borroto-Escuela DO; Pintsuk J; Schäfer T; Friedland K; Ferraro L; Tanganelli S; Liu F; Fuxe K Ther Adv Psychopharmacol; 2016 Apr; 6(2):77-94. PubMed ID: 27141290 [TBL] [Abstract][Full Text] [Related]
12. From dopamine to salience to psychosis--linking biology, pharmacology and phenomenology of psychosis. Kapur S; Mizrahi R; Li M Schizophr Res; 2005 Nov; 79(1):59-68. PubMed ID: 16005191 [TBL] [Abstract][Full Text] [Related]
14. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease. Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597 [TBL] [Abstract][Full Text] [Related]
15. Extending therapeutic use of psychostimulants: focus on serotonin-1A receptor. Haleem DJ Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():170-80. PubMed ID: 23906987 [TBL] [Abstract][Full Text] [Related]
17. Delusional parasitosis: A case series. Gajbhiye A; Ali T; Aziz S; Singh P; Gandhi S; Chaudhury S; Patil J Ind Psychiatry J; 2023 Nov; 32(Suppl 1):S258-S261. PubMed ID: 38370972 [TBL] [Abstract][Full Text] [Related]
18. Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease. Markham A; Benfield P CNS Drugs; 1997 Apr; 7(4):328-40. PubMed ID: 27520755 [TBL] [Abstract][Full Text] [Related]
19. Glutamate N-methyl-D-aspartate and dopamine receptors have contrasting effects on the limbic versus the somatosensory cortex with respect to amphetamine-induced neurodegeneration. Bowyer JF; Delongchamp RR; Jakab RL Brain Res; 2004 Dec; 1030(2):234-46. PubMed ID: 15571672 [TBL] [Abstract][Full Text] [Related]
20. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin. Majlath Z; Obal I; Vecsei L CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]